Gantofiban

Drug Profile

Gantofiban

Alternative Names: EMD 122347; YM 028

Latest Information Update: 08 Jun 2004

Price : $50

At a glance

  • Originator Merck KGaA; Yamanouchi
  • Class Antithrombotics; Oxazoles; Piperazines; Small molecules; Vascular disorder therapies
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 13 May 2004 Discontinued - Phase-II for Thrombosis in Japan (PO)
  • 20 Oct 2003 This compound is still in active development
  • 22 Jul 2002 Phase-II clinical trials in Thrombosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top